Search for a trial

Effectiveness Study of Electrical Stimulation in Prevention of Decubitus

The primary objective of this study is to investigate the effectiveness of electrical stimulation in reducing the incidence of decubitus ulcers on the heel in Intensive Care patients

Comfort and Safety of Electrical Stimulation for Prevention of Decubitus

The primary objectives of this study are: 1. Will there be any adverse events, due to the electrical stimulation?2. Are the sock and the electrical stimulation comfortable for the patient?Our secondary objective is: Are there signs that electrical…

An exploratory trial to assess naturalistic safety and efficacy outcomes in patients trasitioned to ustekinumab from previous methotrexate therapy

Primary Objective: The primary objective of this exploratory trial is to evaluate the comparative safety through Week 12 of two treatment transition strategies in patients with inadequate response to methotrexate: discontinuation of methotrexate…

Psychophysiological stress mechanisms in chronic inflammatory diseases; an experimental study

Referring to the previous CMO approved research proposal (2004/222), in this study the effects of a short-term stressor and a stress-reducing intervention on neuroendocrine, immune and self-reported indicators of stress reactivity in patients with…

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)

The objective of the trial is to assess the efficacy and safety of nintedanib in the treatment ofSSc with ILD at a dose of 150 mg bid compared to placebo.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis

Objectives: The primary objectives of the study are to assess whether 80 mg LY2439821 every 2 weeks (Q2W) or every 4 weeks (Q4W) is:* Superior to placebo at Week 12 in the treatment of patients with moderate-to-severe plaque Ps as measured by: o…

A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)

Primary Trial ObjectivesBase Study1) Primary Efficacy Objective: To assess the efficacy of SCH 900222/MK-3222, hereafter referred to as MK-3222, compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the…